Co-Authors
This is a "connection" page, showing publications co-authored by Frederique Paulus and Lieuwe Bos.
Connection Strength
1.109
-
Assessment of Lung Reaeration at 2 Levels of Positive End-expiratory Pressure in Patients With Early and Late COVID-19-related Acute Respiratory Distress Syndrome. J Thorac Imaging. 2021 Sep 01; 36(5):286-293.
Score: 0.241
-
Practice of adjunctive treatments in critically ill COVID-19 patients-rational for the multicenter observational PRoAcT-COVID study in The Netherlands. Ann Transl Med. 2021 May; 9(9):813.
Score: 0.236
-
Subphenotyping Acute Respiratory Distress Syndrome in Patients with COVID-19: Consequences for Ventilator Management. Ann Am Thorac Soc. 2020 09; 17(9):1161-1163.
Score: 0.225
-
Association of early positive end-expiratory pressure settings with ventilator-free days in patients with coronavirus disease 2019 acute respiratory distress syndrome: A secondary analysis of the Practice of VENTilation in COVID-19 study. Eur J Anaesthesiol. 2021 12 01; 38(12):1274-1283.
Score: 0.061
-
Dead space estimates may not be independently associated with 28-day mortality in COVID-19 ARDS. Crit Care. 2021 05 17; 25(1):171.
Score: 0.059
-
Awake Proning as an Adjunctive Therapy for Refractory Hypoxemia in Non-Intubated Patients with COVID-19 Acute Respiratory Failure: Guidance from an International Group of Healthcare Workers. Am J Trop Med Hyg. 2021 Mar 11; 104(5):1676-1686.
Score: 0.058
-
Instrumental dead space in ventilator management - Authors' reply. Lancet Respir Med. 2021 03; 9(3):e23.
Score: 0.058
-
Ventilation management and clinical outcomes in invasively ventilated patients with COVID-19 (PRoVENT-COVID): a national, multicentre, observational cohort study. Lancet Respir Med. 2021 02; 9(2):139-148.
Score: 0.057
-
PRactice of VENTilation in Patients with Novel Coronavirus Disease (PRoVENT-COVID): rationale and protocol for a national multicenter observational study in The Netherlands. Ann Transl Med. 2020 Oct; 8(19):1251.
Score: 0.057
-
Anti-C5a antibody IFX-1 (vilobelimab) treatment versus best supportive care for patients with severe COVID-19 (PANAMO): an exploratory, open-label, phase 2 randomised controlled trial. Lancet Rheumatol. 2020 Dec; 2(12):e764-e773.
Score: 0.057